美国 · SEC FORM 4
HCW Biologics Inc.
HCWB · Nasdaq · CIK 0001828673 · Healthcare · Biotechnology
内部人信号
4 位买方 · 6 条买入交易行 · $531.7K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ 角色得分低 · 买入者中职位最高的是：Chief Executive Officer（CEO、董事长和持股 10% 以上的股东得分最低）
- ⚠ Purchase activity is becoming less recent
- ✓ Cluster breadth is broad · 4+ insiders
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Chief Executive Officer, Chief Financial Officer, Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 68.8
- 68.7
- 68.7
- 68.6
- 68.4
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -34.2%
- 3M
- -63.8%
- 6M
- -26.9%
- 12M
- -94.5%
波动率与流动性
- 波动率
- 359.2%
- Beta
- —
- 平均每日成交额
- USD 611,837
估值
- 市值
- USD 2.9M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -287.9%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-12 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 60,941
- 上期报告
- 9,274
- 日均成交量
- 1,348,961
- 回补天数
- ≤ 1.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | Wong Hing C | 买入 (P) | Common Stock | 23,210 | USD 2.59 | USD 60,114 | SEC 申报 ↗ |
| 2026-07-29 | GARRETT SCOTT T | 买入 (P) | Common Stock | 7,736 | USD 2.59 | USD 20,036 | SEC 申报 ↗ |
| 2026-07-29 | Flowers Lee | 买入 (P) | Common Stock | 7,736 | USD 2.59 | USD 20,036 | SEC 申报 ↗ |
| 2026-05-22 | Wong Hing C | 买入 (P) | Common Stock | 113,879 | USD 1.41 | USD 160,569 | SEC 申报 ↗ |
| 2026-05-22 | GARRETT SCOTT T | 买入 (P) | Common Stock | 177,936 | USD 1.41 | USD 250,890 | SEC 申报 ↗ |
| 2026-05-22 | Byam Rebecca | 买入 (P) | Common Stock | 14,235 | USD 1.41 | USD 20,071 | SEC 申报 ↗ |
| 2025-05-16 | Wong Hing C | 买入 (P) | Common Stock | 8,054 | USD 7.45 | USD 60,002 | SEC 申报 ↗ |
| 2025-05-16 | Winer Gary M | 买入 (P) | Common Stock | 1,342 | USD 7.45 | USD 9,998 | SEC 申报 ↗ |
| 2025-05-16 | GARRETT SCOTT T | 买入 (P) | Common Stock | 13,423 | USD 7.45 | USD 100,001 | SEC 申报 ↗ |
| 2025-05-08 | Wong Hing C | 买入 (P) | Common Stock | 92,500 | USD 26.00 | USD 2,405,000 | SEC 申报 ↗ |
| 2025-05-08 | Winer Gary M | 买入 (P) | Common Stock | 2,308 | USD 26.00 | USD 60,008 | SEC 申报 ↗ |
| 2025-05-08 | Greene Rick S. | 买入 (P) | Common Stock | 962 | USD 26.00 | USD 25,012 | SEC 申报 ↗ |
| 2025-05-08 | GARRETT SCOTT T | 买入 (P) | Common Stock | 5,385 | USD 26.00 | USD 140,010 | SEC 申报 ↗ |
| 2025-05-08 | Flowers Lee | 买入 (P) | Common Stock | 962 | USD 26.00 | USD 25,012 | SEC 申报 ↗ |
| 2025-05-08 | Byam Rebecca | 买入 (P) | Common Stock | 8,462 | USD 26.00 | USD 220,012 | SEC 申报 ↗ |
Form 4 申报证据
6 transaction lines in the latest 365-day window; 115 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | Wong Hing C | 买入 (P) | Common Stock | 23,210 | USD 2.59 | USD 60,114 | SEC 申报 ↗ |
| 2026-07-29 | GARRETT SCOTT T | 买入 (P) | Common Stock | 7,736 | USD 2.59 | USD 20,036 | SEC 申报 ↗ |
| 2026-07-29 | Flowers Lee | 买入 (P) | Common Stock | 7,736 | USD 2.59 | USD 20,036 | SEC 申报 ↗ |
展开近期 Form 4 证据 (6 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | Wong Hing C | 买入 (P) | Common Stock | 23,210 | USD 2.59 | USD 60,114 | SEC 申报 ↗ |
| 2026-07-29 | GARRETT SCOTT T | 买入 (P) | Common Stock | 7,736 | USD 2.59 | USD 20,036 | SEC 申报 ↗ |
| 2026-07-29 | Flowers Lee | 买入 (P) | Common Stock | 7,736 | USD 2.59 | USD 20,036 | SEC 申报 ↗ |
| 2026-05-22 | Wong Hing C | 买入 (P) | Common Stock | 113,879 | USD 1.41 | USD 160,569 | SEC 申报 ↗ |
| 2026-05-22 | GARRETT SCOTT T | 买入 (P) | Common Stock | 177,936 | USD 1.41 | USD 250,890 | SEC 申报 ↗ |
| 2026-05-22 | Byam Rebecca | 买入 (P) | Common Stock | 14,235 | USD 1.41 | USD 20,071 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | HCWB |
| CIK | 0001828673 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 115 transaction lines from 2021-07-22 to 2026-07-29 91 P purchase lines · 0 S sale lines · 24 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.